Metsera’s new obesity data create side effect and efficacy questions for Pfizer to answer

Pfizer’s back in obesity. Or is it? The hotly-awaited Phase 2b readout of the long-acting GLP-1 shot developed by Metsera, the biotech Pfizer said it would buy for $4.9 billion last week ...